NY-ESO-1 would be a beneficial addition to a cancer vaccine because:
A) It stimulates macrophages
B) It stimulates the production NK cells
C) It stimulates both CD4 and CD8 T cells
D) It stimulates a strong antibody response
Correct Answer:
Verified
Q1: Which of the following is an outcome
Q2: Which is one disadvantage to cell-based anticancer
Q3: What is one role that type I
Q5: A defect in production of cryopyrin leads
Q6: Oprelvekin increases levels of:
A) Platelets
B) Neutrophils
C) Macrophages
D)
Q7: What is the mechanism of action of
Q8: Recombinant IL-2 administration is appropriate for the
Q9: Which of the following may be administered
Q10: Which of the following is a marker
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents